

A background image showing pharmaceutical raw materials. On the left, there is a pile of white powder and a single blue tablet. On the right, there is a pile of white powder and several white tablets. The background is a light, neutral color.

Pharma Raw Material

(API/Bulk Drugs) Manufacturing

Production of
Active Pharma Ingredients (API)

**Cephalexin, Ampicillin Trihydrate,
Ibuprofen and Paracetamol**



Introduction



The active pharmaceutical ingredient (API) is that the part of any drug that produces the intended effects. Some drugs, similar to combination therapies, have multiple active ingredients to treat different symptoms or act in different ways in which.

For example, if the API may be a solid and therefore the drug is required to have a liquid dose kind, such as a cough syrup, then the excipients would be the liquids that are used to formulate the syrup. the design criteria for any little molecule API is usually a combination of many factors that goes on the far side the intended therapeutic effect, and usually heavily encompasses each pharmacokinetic and pharmacodynamics considerations, so for this reason, API molecules have many chemical functional groups.

Related Books: - [Pharmaceutical, Drugs, Proteins Technology Handbooks](#)

Production of APIs has traditionally been done by the pharmaceutical companies themselves in their home countries. However in recent years many corporations have opted to send manufacturing overseas to cut costs. This has caused significant changes to however these medicines are regulated, with a lot of rigorous guidelines and inspections put into place.

Cefalexin, is an antibiotic that can treat a number of bacterial infections. It kills gram-positive and some gram-negative bacteria by disrupting the growth of the bacterial cell wall. Cefalexin may be a beta-lactam antibiotic within the category of first-generation cephalosporins. It works similarly to different agents inside this class, as well as blood vessel cefazolin, however may be taken orally.

Related Projects: - [Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates](#)

Ampicillin is an antibiotic used to prevent and treat variety of bacterial infections, similar to respiratory tract infections, tract infections, meningitis, salmonellosis, and endocarditis. It should also be used to forestall group b streptococcal infection in newborns. It's used by mouth, by injection into a muscle, or intravenously. Like all antibiotics, it's not helpful for the treatment of viral infections.

Related Videos: - [Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Pharmaceutical Bulk Drugs](#)



Paracetamol (acetaminophen) is a pain reliever yet a fever reducer. The exact mechanism concerning action about is not known. Paracetamol is back in conformity with deal with many conditions such as headache, muscle aches, arthritis, backache, toothaches, colds, yet fevers. It relieves pain between slight arthritis but has no effect about the underlying inflammation and swelling of the joint. Paracetamol may additionally also be used for other purposes not listed into this medication guide.

It is the almost commonly used medication for pain then fever in both the United States and Europe. It is over the World Health Organization's List on Essential Medicines, the safest yet almost effective medicines wished in a health system. Paracetamol is available namely a regular medication including trade names together with Tylenol then Panadol, amongst others.

Paracetamol is chronic because the remedy regarding slight to reasonable pain. The utilizes over the intravenous structure for short-term pain into human beings in the emergency department is supported by way of limited evidence. In adults that seems to remain beneficial because migraines, tension headaches, perineal pain after childbirth, and kidney stone pain.

Related Videos: - [Active Pharma Ingredients \(API\) - Global Market Estimated to Reach US\\$ 21.9 billion by 2023](#)



Ibuprofen is a medication in the non-steroidal anti-inflammatory drug class that is used for treating pain, fever, and inflammation. This includes onerous menstrual periods, migraines, and rheumatoid arthritis. It may also be used in imitation of close a patent ductus arteriosus within a premature baby. Ibuprofen is used after reduce fever then treat pain or inflammation caused by dense conditions certain as headache, toothache, back pain, arthritis, menstrual cramps, or minor injury.

Related Videos:- [Investment Opportunities in API Bulk Drugs & Intermediates Manufacturing Unit](#)



Market Outlook

The API need is surging due to the improved demand because pharmaceutical drugs, which between turn is driven through the growing old population, rising incidence of continual diseases such as like cancer, diabetes, cardiovascular, neurological yet infectious diseases. India then China are the major suppliers concerning APIs according to North America due to their paltry production capacities, labor charges yet the presence concerning a large range concerning global and domestic players. In method to cut down of expenses and make bigger profits, companies have begun outsourcing the introduction over APIs according to the developing countries between Asia, leading to boom of the Asian market.

Related Videos:- [Manufacturing Business Ideas in Pharmaceutical Industry](#)

India's reliance over pharma part imports has risen upstairs the previous not many decades due in accordance with the higher virtue concerning domestic production, together with the cost gap reaching as a lot as 20%-30%, particularly for energy-intensive fermentation-based ingredients used into anti-infectives. Import dependence is extra than 90% because partial life-saving drugs, such as penicillin or ciprofloxacin.

We trust the government announcement, which includes production-linked incentives and financial assistance schemes aggregating in accordance with USD1.3 billion, choice help address the two keys issues; the higher price on domestic production compared along imports then funding requirement according to put in on the necessary [infrastructure](#).

Related Projects:- [Startup Opportunities in Active Pharma Ingredients](#)

India Readies \$1.3 Billion Pharma Incentive Scheme; Aims to Be \$120 Billion Industry

Even as China settles down post COVID-19, the Indian pharmaceutical business is bracing itself for a reduction in profit margins within the short term, given the expected rise in the costs of active pharmaceutical ingredients (API) and key beginning materials (KSM). Aiming to scale back import dependency and self-reliance and drug security, the Indian government has determined to produce incentives to the pharmaceutical industry, reports the pharmaceutical company Letter's India correspondent.

Final pointers for a Production connected Incentive (PLI) Scheme are being deliberated in government circles, with the govt. shortly to unveil a \$1.3 billion arrange to boost domestic API and KSM production.

Market Research Reports:- India Active Pharmaceutical Ingredient (API)

The scheme involves providing PLIs price \$911 million to firms which will invest in domestic producing of vital KSMs required to produce APIs. Another \$393 million has been reserved for creating bulk-drug parks in varied states. An official Said \$181 million of this quantity has been reserved for 23 chemical synthesis-based [API](#) as well as hypertension medication such as losartan and valsartan, anti-HIV medication such as lopinavir and ritonavir, also as cholesterol-lowering drugs comparable to atorvastatin. While \$131 million has been reserved for 20 beneficiary companies who are to require up niche fermentation-based product categories comparable to cyclines used for doxycycline, aminoglycoside for gentamicin, streptomycin, steroids, anti-TB medication like rifampicin, vitamins and lincosamides, up to \$125 million has been reserved for 16 beneficiaries who are to require up production of four crucial KSMs made through [chemical](#) synthesis.

Active Pharmaceutical Ingredients Market Dynamics

The growing cases of chronic diseases are one in all the leading causes of hospitalization, and a majority of the patients with these conditions may have re-admission in hospitals because of infection leading in alternative chronic diseases. For instance, in line with the report revealed by the Centers for Disease Control and Prevention (CDC), nearly 92.1 million adults within the US proscribed a minimum of one style of cardiovascular disease in 2017. Besides, agency has conjointly expressed that out of the total annual [health care](#) expenditure, i.e. USD 27 trillion, 86% is for the people with chronic health conditions within the US.

Related Projects: - **[Investment Opportunities in API Bulk Drugs & Intermediates Manufacturing Unit](#)**

The Indian pharmaceutical business is that the third largest within the world by volume and 14th largest in terms of value. India contributes 3.5 per cent of total drugs and medicines exported globally. Despite these achievements, India is significantly dependent on import of some basic raw materials, viz., bulk drugs used to turn out finished indefinite quantity formulations. India imports bulk drugs largely for economic reasons. Chinese bulk drugs are cheaper by 25-30 per cent on average, compared to domestic products. However, the recent Covid-19 pandemic and step-up at the border have exposed India's vulnerability in this area. One can get to invest Rs 20 crore integer to line up new facility — this may be on the premises of AN existing plant and build the chosen bulk drugs to avail of the scheme. India is that the seventh largest country within the world and has the second highest population. It a parliamentary democratic form of government and has plenteous natural resources and sufficient oil reserves.

Related Projects:- Active Pharma Ingredients (api) (cephalexin, Ampicillin Trihydrate, Ibuprofen And Paracetamol)

Specialty Medicines a Trend in the Active Pharmaceutical Ingredients Market

A higher generic adoption rate in developed countries that ranges from 27% to 32% is driving global medicine spending and aiding greater access to improved, lifesaving healthcare services. The adoption of branded generic drugs is predicted to be higher in emerging economies such as China and India and generic drugs accounted for nearly 80% of the total drugs sold by value in these fast-growing nations. Rising use of specialty medicines is anticipated to grow the pharmaceutical spending worldwide with quicker growth in richer, developed nations as compared to their emerging counterparts. This is primarily because the former have adequate manufacturing units, a higher spending power, and greater emphasis on transparent pricing by assessing measuring effects on the population.

Related Projects: - Active Pharma Ingredients (API)

[Focus On Healthcare to Drive the Active Pharmaceutical Ingredients Market](#)

The spending on [healthcare](#) has grown at a rapid pace in recent years and it increased at a CAGR of 6.92% between the years 2003 and 2013. The healthcare spending growth was significantly higher than the population growth rate that grew at a CAGR of 1.22% for the same period. The per capita healthcare spending rose from just under US\$ 600 in 2003 to above US\$ 1000 in 2013, at an average CAGR of 5.62%. The focus on healthcare spending was observed to be a global phenomenon and this directly benefited the active [pharmaceutical](#) ingredients market.

Projects: - [Project Reports & Profiles](#)

[Role of Government Towards API](#)

The coronavirus outbreak disrupting supply of [active pharmaceutical ingredients](#) (APIs) and medical devices from China to [India](#), the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk [drugs](#) and medical devices in the country and their exports.

On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively.



The Cabinet also approved a scheme on promotion of bulk [drug](#) parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk [Drug](#) Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc.

The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/[drug](#) intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years.

Financial incentive will be given to eligible manufacturers of identified 53 critical [bulk drugs](#) on their incremental sales over the base year (2019-20) for a period of 6 years.

Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs.

Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs.

Books:- BOOKS & DATABASES

The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years.

The drug industry has welcomed the incentives offered by the government to promote API units in India.



Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore.

The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years.

Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices.

Market Research:- Market Research Reports

Union Cabinet scheme on Promotion of Bulk Drug Parks

- The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years.
- Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years.

Related Projects:- Active Pharma Ingredients (api)



Details:

Promotion of Bulk Drug Parks

- Decision is to develop 3 mega Bulk Drug parks in India in partnership with States.
- Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park.
- Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc.
- A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years.

Related Projects:- [Manufacturing Of Active Pharma Ingredients \(api\)](#)

Production Linked Incentive Scheme

- Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years.
- Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs.
- Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs.
- A sum of Rs. 6,940 crore has been approved for next 8 years.



Key Players

Alpha Remedies Ltd.

Ankur Drugs & Pharma Ltd.

Aurobindo Pharma Ltd.

Cian Healthcare Ltd

Cipla Ltd.

Dr. Reddy'S Laboratories Ltd.

Farmson Pharmaceutical Gujarat Pvt. Ltd.

Glaxosmithkline Pharmaceuticals Ltd.

Indoco Remedies Ltd.

Pan Drugs Ltd.

Piramal Enterprises Ltd.

Sanofi India Ltd.

Sri Krishna Pharmaceuticals Ltd.

Teva Pharmaceutical & Chemical Inds. India Pvt. Ltd.

Triton Laboratories Ltd.



Machinery Photographs



FLUIDISED BED DRYER



JACKETED REACTOR



STORAGE TANK



DISTILLATION ASSEMBLY

Project at a Glance

COST OF PROJECT				MEANS OF FINANCE			
Particulars	Existing	Proposed	Total	Particulars	Existing	Proposed	Total
Land & Site Development Exp.	0.00	290.00	290.00	Capital	0.00	414.00	414.00
Buildings	0.00	413.00	413.00	Share Premium	0.00	0.00	0.00
Plant & Machineries	0.00	347.00	347.00	Other Type Share Capital	0.00	0.00	0.00
Motor Vehicles	0.00	10.00	10.00	Reserves & Surplus	0.00	0.00	0.00
Office Automation Equipments	0.00	65.00	65.00	Cash Subsidy	0.00	0.00	0.00
Technical Knowhow Fees & Exp.	0.00	50.00	50.00	Internal Cash			
Franchise & Other Deposits	0.00	0.00	0.00	Accruals	0.00	0.00	0.00
Preliminary & Pre-operative Exp	0.00	5.00	5.00	Long/Medium Term Borrowings	0.00	1242.01	1242.01
Provision for Contingencies	0.00	32.00	32.00	Debentures / Bonds Unsecured	0.00	0.00	0.00
Margin Money - Working Capital	0.00	444.01	444.01	Loans/Deposits	0.00	0.00	0.00
TOTAL	0.00	1656.01	1656.01	TOTAL	0.00	1656.01	1656.01

Project at a Glance

Year	Annualised		Book Value	Debt	Dividend	Retained Earnings		Payout	Probable Market Price	P/E Ratio	Yield Price/Book Value
	EPS	CEPS	Per Share		Per Share	Per Share		%		No. of Times	%
1-2	7.66	10.32	17.66	24.00	0.00	100.00	7.66	0.00	7.66	1.00	0.00
2-3	10.40	12.74	28.06	18.00	0.00	100.00	10.40	0.00	10.40	1.00	0.00
3-4	13.21	15.26	41.27	12.00	0.00	100.00	13.21	0.00	13.21	1.00	0.00
4-5	15.93	17.74	57.20	6.00	0.00	100.00	15.93	0.00	15.93	1.00	0.00
5-6	18.55	20.15	75.75	0.00	0.00	100.00	18.55	0.00	18.55	1.00	0.00

Project at a Glance

Year	D. S. C. R.			Debt / Equity - Deposits Debt	Equity as- Equity	Total Net Worth	Return on Net Worth	Profitability Ratio					Assets Turnover Ratio	Current Ratio
	Individual	Cumulative	Overall					GPM	PBT	PAT	Net Contribution	P/V Ratio		
	(Number of times)			(Number of times)		%	%	%	%	%	%			
Initial				3.00	3.00									
1-2	1.49	1.49		1.36	1.36	5.08	4.69%	2.64%	1.74%	1852.81	10.19%	4.13	1.13	
2-3	1.82	1.65		0.64	0.64	3.35	5.02%	3.15%	2.03%	1871.14	8.82%	4.24	1.19	
3-4	2.22	1.83	2.22	0.29	0.29	2.39	5.24%	3.54%	2.26%	2131.53	8.79%	4.21	1.27	
4-5	2.68	2.02		0.10	0.10	1.81	5.39%	3.81%	2.42%	2391.92	8.77%	4.12	1.36	
5-6	3.22	2.22		0.00	0.00	1.43	5.48%	4.01%	2.53%	2652.31	8.75%	3.99	1.53	

Project at a Glance

BEP	
BEP - Maximum Utilisation Year	5
Cash BEP (% of Installed Capacity)	49.91%
Total BEP (% of Installed Capacity)	52.41%
IRR, PAYBACK and FACR	
Internal Rate of Return .. (In %age)	31.72%
Payback Period of the Project is (In Years)	2 Years 3 Months
Fixed Assets Coverage Ratio (No. of times)	38.626

Major Queries/Questions Answered in the Report?

- 1. What is Active Pharma Ingredients (API) Manufacturing industry ?**
- 2. How has the Active Pharma Ingredients (API) Manufacturing industry performed so far and how will it perform in the coming years ?**
- 3. What is the Project Feasibility of Active Pharma Ingredients (API) Manufacturing Plant ?**
- 4. What are the requirements of Working Capital for setting up Active Pharma Ingredients (API) Manufacturing plant ?**

- 5. What is the structure of the Active Pharma Ingredients (API) Manufacturing Business and who are the key/major players ?**
- 6. What is the total project cost for setting up Active Pharma Ingredients (API) Manufacturing Business?**
- 7. What are the operating costs for setting up Active Pharma Ingredients (API) Manufacturing plant ?**
- 8. What are the machinery and equipment requirements for setting up Active Pharma Ingredients (API) Manufacturing plant ?**

- 9. Who are the Suppliers and Manufacturers of Plant & Machinery for setting up Active Pharma Ingredients (API) Manufacturing plant ?**
- 10. What are the requirements of raw material for setting up Active Pharma Ingredients (API) Manufacturing plant ?**
- 11. Who are the Suppliers and Manufacturers of Raw materials for setting up Active Pharma Ingredients (API) Manufacturing Business?**
- 12. What is the Manufacturing Process of Active Pharma Ingredients (API) ?**

- 13. What is the total size of land required for setting up Active Pharma Ingredients (API) Manufacturing plant ?**
- 14. What will be the income and expenditures for Active Pharma Ingredients (API) Manufacturing Business?**
- 15. What are the Projected Balance Sheets of Active Pharma Ingredients (API) Manufacturing plant ?**
- 16. What are the requirement of utilities and overheads for setting up Active Pharma Ingredients (API) Manufacturing plant?**
- 17. What is the Built up Area Requirement and cost for setting up Active Pharma Ingredients (API) Manufacturing Business?**



- 18. What are the Personnel (Manpower) Requirements for setting up Active Pharma Ingredients (API) Manufacturing Business?**
- 19. What are Statistics of Import & Export for Active Pharma Ingredients (API) ?**
- 20. What is the time required to break-even of Active Pharma Ingredients (API) Manufacturing Business?**
- 21. What is the Break-Even Analysis of Active Pharma Ingredients (API) Manufacturing plant?**
- 22. What are the Project financials of Active Pharma Ingredients (API) Manufacturing Business?**

- 23. What are the Profitability Ratios of Active Pharma Ingredients (API) Manufacturing Project?**
- 24. What is the Sensitivity Analysis-Price/Volume of Active Pharma Ingredients (API) Manufacturing plant?**
- 25. What are the Projected Pay-Back Period and IRR of Active Pharma Ingredients (API) Manufacturing plant?**
- 26. What is the Process Flow Sheet Diagram of Active Pharma Ingredients (API) Manufacturing project?**

27. What are the Market Opportunities for setting up Active Pharma Ingredients (API) Manufacturing plant?

28. What is the Market Study and Assessment for setting up Active Pharma Ingredients (API) Manufacturing Business?

29. What is the Plant Layout for setting up Active Pharma Ingredients (API) Manufacturing Business?

Table of Contents of the Project Report

1 PROJECT LOCATION

- 1.1. DISTRICT PROFILE & GEOTECHNICAL SITE CHARACTERIZATION
 - 1.1.1. General
 - 1.1.2. Location & Geographical Area
 - 1.1.3. Climate
 - 1.1.4. Administration
 - 1.1.5. Demographics
 - 1.1.6. Map
 - 1.1.7. Culture and Attitudes
 - 1.1.8. Economy
 - 1.1.9. Transport

2. INTRODUCTION

3. CEFALLEXIN

- 3.1. MEDICAL USES
- 3.2. INFECTIONS
- 3.3. FORMULATIONS
- 3.4. CHEMICAL AND PHYSICAL PROPERTIES

3.5. BRIEF DESCRIPTION OF MANUFACTURING PROCESS OF
CEPHALEXIN MONO HYDRATE

3.6. PROCESS FLOW DIAGRAM

4. AMPICILLIN TRIHYDRATE

4.1. CHEMICAL AND PHYSICAL PROPERTIES

4.2. MEDICAL USES

4.3. VETERINARY USE

4.4. BRIEF DESCRIPTION OF MANUFACTURING PROCESS OF
AMPICILLIN TRIHYDRATE

4.5. PROCESS FLOW DIAGRAM

5. PARACETAMOL

5.1. MEDICAL USES

5.2. RAW MATERIAL

5.2.1. 4-Nitrophenol

5.2.2. Acetic Acid

5.2.3. Methanol

5.3. BRIEF DESCRIPTION OF MANUFACTURING PROCESS OF
PARACETAMOL

5.4. PROCESS FLOW DIAGRAM

6. IBUPROFEN

- 6.1. PROPERTIES
- 6.2. RAW MATERIAL
- 6.3. BRIEF DESCRIPTION OF MANUFACTURING PROCESS OF IBUPROFEN
- 6.4. DESCRIPTION
- 6.5. PROCESS FLOW DIAGRAM

7. MARKET SURVEY

- 7.1. API MANUFACTURERS IN INDIA
- 7.2. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
 - 7.2.1. Industry Insights
 - 7.2.2. Application Insights
 - 7.2.3. Regional Insights
 - 7.2.4. Market Share Insights
- 7.3. KEY PLAYERS IN THE GLOBAL APIS MARKET

7.4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENT

- 7.4.1. Market Dynamics
- 7.4.2. Market Regional Analysis
- 7.4.3. Market Drivers and Key Restraints
- 7.4.4. Market Trends
- 7.4.5. Market Segmentation
- 7.4.6. Market Regional Outlook

7.5. ACTIVE PHARMACEUTICAL INGREDIENTS

- 7.5.1. Market Dynamics
- 7.5.2. Market Segmentations
- 7.5.3. Market Regional Analysis
- 7.5.4. Market Key Players

8. MAJOR FIVE ACTIVE PHARMACEUTICAL INGREDIENTS COMPANIES

9. EXPORT & IMPORT: ALL COUNTRIES

9.1. EXPORT: ALL COUNTRIES

9.1.1. Ampicilline and Its Salts

9.1.2. Cephalexin and Its Salts

9.1.3. Ibuprofen with or without Paracetamol or other Compounds

9.2. IMPORT: ALL COUNTRIES

9.2.1. Ampicilline and Its Salts

9.2.2. Cephalexin and Its Salts

9.2.3. Ibuprofen with or without Paracetamol or other Compounds

10. FINANCIALS & COMPARISON OF MAJOR INDIAN PLAYERS/COMPANIES

10.1. ABOUT FINANCIAL STATEMENTS OF CMIE DATABASE

10.2. PROFITS & APPROPRIATIONS

10.3. TOTAL LIABILITIES

10.4. TOTAL ASSETS

10.5. NET CASH FLOW FROM OPERATING ACTIVITIES

10.6. SECTION -I

- 10.6.1. Name of Company with Contact Details
- 10.6.2. Name of Director(S)
- 10.6.3. Plant Capacity
- 10.6.4. Location of Plant
- 10.6.5. Credit Ratings
- 10.6.6. Name of Raw Material(S) Consumed with Quantity & Cost

10.7. SECTION-II

- 10.7.1. Assets
- 10.7.2. Cash Flow
- 10.7.3. Cost as % Ge of Sales
- 10.7.4. Forex Transaction
- 10.7.5. Growth in Assets & Liabilities
- 10.7.6. Growth in Income & Expenditure
- 10.7.7. Income & Expenditure
- 10.7.8. Liabilities
- 10.7.9. Liquidity Ratios

- 10.7.10. Profitability Ratio
- 10.7.11. Profits
- 10.7.12. Return Ratios
- 10.7.13. Structure of Assets & Liabilities(%)
- 10.7.14. Working Capital & Turnover Ratios

11. COMPANY PROFILE OF MAJOR PLAYERS

12. EXPORT & IMPORT STATISTICS OF INDIA

- 12.1. EXPORT STATISTICS FOR ACTIVE PHARMA INGREDIENT
- 12.2. IMPORT STATISTICS FOR ACTIVE PHARMA INGREDIENT

13. PRESENT MANUFACTURERS

14. BUYER'S LIST

- 14.1. CONTACT DETAILS OF BUYER'S
- 14.2. NAME OF DIRECTOR(S)
- 14.3. PLANT CAPACITY
- 14.4. CREDIT RATINGS
- 14.5. COMPANY WISE CONSUMPTION DETAIL OF THE RAW MATERIALS

15. SUPPLIERS OF PLANT & MACHINERY

16. SUPPLIERS OF RAW MATERIAL

17. PHOTOGRAPHS/IMAGES FOR REFERENCE

- 17.1. MACHINERY PHOTOGRAPHS
- 17.2. RAW MATERIAL PHOTOGRAPHS
- 17.3. PRODUCT PHOTOGRAPHS

18. PLANT LAYOUT

Project Financials

• Project at a Glance	Annexure
• Assumptions for Profitability workings	1
• Plant Economics.....	2
• Production Schedule.....	3
• Land & Building.....	4
Factory Land & Building	
Site Development Expenses	



- **Plant & Machinery.....5**
 - Indigenous Machineries**
 - Other Machineries (Miscellaneous, Laboratory etc.)**

- **Other Fixed Assets.....6**
 - Furniture & Fixtures**
 - Pre-operative and Preliminary Expenses**
 - Technical Knowhow**
 - Provision of Contingencies**

- **Working Capital Requirement Per Month.....7**
 - Raw Material**
 - Packing Material**
 - Lab & ETP Chemical Cost**
 - Consumable Store**

- **Overheads Required Per Month and Per Annum.....8**
 - Utilities & Overheads (Power, Water and Fuel Expenses etc.)**
 - Royalty and Other Charges**
 - Selling and Distribution Expenses**
- **Salary and Wages9**
- **Turnover Per Annum10**
- **Share Capital.....11**
 - Equity Capital**
 - Preference Share Capital**

- **Annexure 1 :: Cost of Project and Means of Finance**
- **Annexure 2 :: Profitability and Net Cash Accruals**
 - **Revenue/Income/Realisation**
 - **Expenses/Cost of Products/Services/Items**
 - **Gross Profit**
 - **Financial Charges**
 - **Total Cost of Sales**
 - **Net Profit After Taxes**
 - **Net Cash Accruals**

- **Annexure 3 :: Assessment of Working Capital requirements**
 - **Current Assets**
 - **Gross Working Capital**
 - **Current Liabilities**
 - **Net Working Capital**
 - **Working Note for Calculation of Work-in-process**

- **Annexure 4 :: Sources and Disposition of Funds**



- **Annexure 5 :: Projected Balance Sheets**

- **ROI (Average of Fixed Assets)**
- **RONW (Average of Share Capital)**
- **ROI (Average of Total Assets)**

- **Annexure 6 :: Profitability Ratios**

- **D.S.C.R**
- **Earnings Per Share (EPS)**
- **Debt Equity Ratio**

- **Annexure 7 :: Break-Even Analysis**

- **Variable Cost & Expenses**
- **Semi-Variable/Semi-Fixed Expenses**
- **Profit Volume Ratio (PVR)**
- **Fixed Expenses / Cost**
- **B.E.P**

- **Annexure 8 to 11 :: Sensitivity Analysis-Price/Volume**

- **Resultant N.P.B.T**
- **Resultant D.S.C.R**
- **Resultant PV Ratio**
- **Resultant DER**
- **Resultant ROI**
- **Resultant BEP**

- **Annexure 12 :: Shareholding Pattern and Stake Status**

- **Equity Capital**
- **Preference Share Capital**

- **Annexure 13 :: Quantitative Details-Output/Sales/Stocks**

- **Determined Capacity P.A of Products/Services**
- **Achievable Efficiency/Yield % of Products/Services/Items**
- **Net Usable Load/Capacity of Products/Services/Items**
- **Expected Sales/ Revenue/ Income of Products/ Services/ Items**

- **Annexure 14** :: **Product wise Domestic Sales Realisation**
- **Annexure 15** :: **Total Raw Material Cost**
- **Annexure 16** :: **Raw Material Cost per unit**
- **Annexure 17** :: **Total Lab & ETP Chemical Cost**
- **Annexure 18** :: **Consumables, Store etc.**
- **Annexure 19** :: **Packing Material Cost**
- **Annexure 20** :: **Packing Material Cost Per Unit**

- **Annexure 21** :: **Employees Expenses**
- **Annexure 22** :: **Fuel Expenses**
- **Annexure 23** :: **Power/Electricity Expenses**
- **Annexure 24** :: **Royalty & Other Charges**
- **Annexure 25** :: **Repairs & Maintenance Expenses**
- **Annexure 26** :: **Other Manufacturing Expenses**
- **Annexure 27** :: **Administration Expenses**
- **Annexure 28** :: **Selling Expenses**

- **Annexure 29 :: Depreciation Charges – as per Books (Total)**
- **Annexure 30 :: Depreciation Charges – as per Books (P & M)**
- **Annexure 31 :: Depreciation Charges - as per IT Act WDV (Total)**
- **Annexure 32 :: Depreciation Charges - as per IT Act WDV (P & M)**
- **Annexure 33 :: Interest and Repayment - Term Loans**
- **Annexure 34 :: Tax on Profits**
- **Annexure 35 :: Projected Pay-Back Period and IRR**

Reasons for Buying our Report:

- **This report helps you to identify a profitable project for investing or diversifying into by throwing light to crucial areas like industry size, market potential of the product and reasons for investing in the product**
- **This report provides vital information on the product like it's characteristics and segmentation**
- **This report helps you market and place the product correctly by identifying the target customer group of the product**

- **This report helps you understand the viability of the project by disclosing details like machinery required, project costs and snapshot of other project financials**
- **The report provides a glimpse of government regulations applicable on the industry**
- **The report provides forecasts of key parameters which helps to anticipate the industry performance and make sound business decisions**

Our Approach:

- **Our research reports broadly cover Indian markets, present analysis, outlook and forecast for a period of five years.**
- **The market forecasts are developed on the basis of secondary research and are cross-validated through interactions with the industry players**
- **We use reliable sources of information and databases. And information from such sources is processed by us and included in the report**

Scope of the Report

The report titled “Market Survey cum Detailed Techno Economic Feasibility Report on Active Pharma Ingredients (API) .” provides an insight into Active Pharma Ingredients (API) market in India with focus on uses and applications, Manufacturing Process, Process Flow Sheets, Plant Layout and Project Financials of Active Pharma Ingredients (API) project. The report assesses the market sizing and growth of the Indian Active Pharma Ingredients (API) Industry. While expanding a current business or while venturing into new business, entrepreneurs are often faced with the dilemma of zeroing in on a suitable product/line. And before diversifying/venturing into any product, they wish to study the following aspects of the identified product:

- **Good Present/Future Demand**
- **Export-Import Market Potential**
- **Raw Material & Manpower Availability**
- **Project Costs and Payback Period**

We at NPCS, through our reliable expertise in the project consultancy and market research field, have demystified the situation by putting forward the emerging business opportunity in the Active Pharma Ingredients (API) sector in India along with its business prospects. Through this report we have identified Active Pharma Ingredients (API) project as a lucrative investment avenue.

Tags

#Activepharmaingredients #pharmaingredients #IndianPharma
#medicineingredients #paracetamolingredients #Paracetamol
#CoronavirusBusiness #COVID2019 #lockdownbusiness
#coronavirusbusiness #Entrepreneurs #covid19business
#DetailedProjectReport #businessconsultant #BusinessPlan
#feasibilityReport #NPCS #industrialproject #entrepreneurindia
#startupbusiness #startupbusinessideas #businessesstart #startupideas
#startupbusinesswithnomoney #businessstartupindia #API #cephalexin
#AmpicillinTrihydrate #Ibuprofen #healthcare #APIBusiness
#apimanufacturing #Apiproduction #APImarket #APIProject #ApiStartup
#APIindustry

NIIR PROJECT CONSULTANCY SERVICES (NPCS)

can provide Detailed Project Report on

Active Pharma Ingredients (API)

**(Cephalexin, Ampicillin Trihydrate, Ibuprofen
and Paracetamol)**

See more

Project Reports & Profiles

BOOKS

Market Research Report

Visit us at

www.entrepreneurindia.co

www.niir.org

**Take a look at
Niir Project Consultancy Services
on #Street View**

<https://goo.gl/VstWkd>

*Locate us on
Google Maps*

<https://goo.gl/maps/BKkUtq9gevT2>

OUR CLIENTS

Our inexhaustible Client list includes public-sector companies, Corporate Houses, Government undertaking, individual entrepreneurs, NRI, Foreign investors, non-profit organizations and educational institutions from all parts of the World. The list is just a glimpse of our esteemed & satisfied Clients.

Click here to take a look
<https://goo.gl/G3ICjV>

Select and Choose the Right Business Startup for You

(Instant Online Project Identification and Selection)

Finding the right startup business is one of the most popular subject today. Starting a business is no easy endeavor, but the time, effort, and challenges can be worth it if you succeed. To give yourself the best chance to be successful, take your time to carefully find the right business for you. We, at NPCS, endeavor to make business selection a simple and convenient step for any entrepreneur/startup. Our expert team, by capitalizing on its dexterity and decade's long experience in the field, has created a list of profitable ventures for entrepreneurs who wish to diversify or venture. The list so mentioned is updated regularly to give you a regular dose of new emerging opportunities.

Visit: <https://www.entrepreneurindia.co/project-identification>

[Download Complete List of Project Reports:](#)

▪ [Detailed Project Reports](#)

Visit:- <https://www.entrepreneurindia.co/complete-project-list>

NPCS is manned by engineers, planners, specialists, financial experts, economic analysts and design specialists with extensive experience in the related industries.

Our Market Survey cum Detailed Techno Economic Feasibility Report provides an insight of market in India. The report assesses the market sizing and growth of the Industry. While expanding a current business or while venturing into new business, entrepreneurs are often faced with the dilemma of zeroing in on a suitable product/line.

And before diversifying/venturing into any product, they wish to study the following aspects of the identified product:

- **Good Present/Future Demand**
- **Export-Import Market Potential**
- **Raw Material & Manpower Availability**
- **Project Costs and Payback Period**

The detailed project report covers all aspect of business, from analyzing the market, confirming availability of various necessities such as Manufacturing Plant, Detailed Project Report, Profile, Business Plan, Industry Trends, Market Research, Survey, Manufacturing Process, Machinery, Raw Materials, Feasibility Study, Investment Opportunities, Cost and Revenue, Plant Economics, Production Schedule,

Working Capital Requirement, uses and applications, Plant Layout, Project Financials, Process Flow Sheet, Cost of Project, Projected Balance Sheets, Profitability Ratios, Break Even Analysis. The DPR (Detailed Project Report) is formulated by highly accomplished and experienced consultants and the market research and analysis are supported by a panel of experts and digitalized data bank.

We at NPCS, through our reliable expertise in the project consultancy and market research field, have demystified the situation by putting forward the emerging business opportunity in India along with its business prospects.....[Read more](#)



Contact us

NIIR PROJECT CONSULTANCY SERVICES

**106-E, Kamla Nagar, Opp. Mall ST,
New Delhi-110007, India.**

Email: npcs.ei@gmail.com , info@entrepreneurindia.co

Tel: +91-11-23843955, 23845654, 23845886

Mobile: +91-9097075054, 8800733955

Fax: +91-11-23845886

Website : www.entrepreneurindia.co , www.niir.org

Take a look at *NIIR PROJECT CONSULTANCY SERVICES* on #StreetView

<https://goo.gl/VstWkd>



Niir PROJECT CONSULTANCY SERVICES

AN ISO 9001: 2015 CERTIFIED COMPANY

Who are we?

- *One of the leading reliable names in industrial world for providing the most comprehensive technical consulting services*
- *We adopt a systematic approach to provide the strong fundamental support needed for the effective delivery of services to our Clients' in India & abroad*

We at NPCS want to grow with you by providing solutions scale to suit your new operations and help you reduce risk and give a high return on application investments. We have successfully achieved top-notch quality standards with a high level of customer appreciation resulting in long lasting relation and large amount of referral work through technological breakthrough and innovative concepts. A large number of our Indian, Overseas and NRI Clients have appreciated our expertise for excellence which speaks volumes about our commitment and dedication to every client's success.

We bring deep, functional expertise, but are known for our holistic perspective: we capture value across boundaries and between the silos of any organization. We have proven a multiplier effect from optimizing the sum of the parts, not just the individual pieces. We actively encourage a culture of innovation, which facilitates the development of new technologies and ensures a high quality product.

What do we offer?

- *Project Identification*
- *Detailed Project Reports/Pre-feasibility Reports*
- *Market Research Reports*
- *Business Plan*
- *Technology Books and Directory*
- *Industry Trend*
- *Databases on CD-ROM*
- *Laboratory Testing Services*
- *Turnkey Project Consultancy/Solutions*
- *Entrepreneur India (An Industrial Monthly Journal)*

How are we different ?

- *We have two decades long experience in project consultancy and market research field*
- *We empower our customers with the prerequisite know-how to take sound business decisions*
- *We help catalyze business growth by providing distinctive and profound market analysis*
- *We serve a wide array of customers , from individual entrepreneurs to Corporations and Foreign Investors*
- *We use authentic & reliable sources to ensure business precision*

Our Approach

Requirement collection

Thorough analysis of the project

Economic feasibility study of the Project

Market potential survey/research

Report Compilation

Who do we Serve?

- Public-sector Companies
- Corporates
- Government Undertakings
- Individual Entrepreneurs
- NRI's
- Foreign Investors
- Non-profit Organizations, NBFC's
- Educational Institutions
- Embassies & Consulates
- Consultancies
- Industry / trade associations

Sectors We Cover

- Ayurvedic And Herbal Medicines, Herbal Cosmetics
- Alcoholic And Non Alcoholic Beverages, Drinks
- Adhesives, Industrial Adhesive, Sealants, Glues, Gum & Resin
- Activated Carbon & Activated Charcoal
- Aluminium And Aluminium Extrusion Profiles & Sections,
- Bio-fertilizers And Biotechnology
- Breakfast Snacks And Cereal Food
- Bicycle Tyres & Tubes, Bicycle Parts, Bicycle Assembling

Sectors We Cover *Conti...*

- Bamboo And Cane Based Projects
- Building Materials And Construction Projects
- Biodegradable & Bioplastic Based Projects
- Chemicals (Organic And Inorganic)
- Confectionery, Bakery/Baking And Other Food
- Cereal Processing
- Coconut And Coconut Based Products
- Cold Storage For Fruits & Vegetables
- Coal & Coal Byproduct

Sectors We Cover *Cont...*

- Copper & Copper Based Projects
- Dairy/Milk Processing
- Disinfectants, Pesticides, Insecticides, Mosquito Repellents,
- Electrical, Electronic And Computer based Projects
- Essential Oils, Oils & Fats And Allied
- Engineering Goods
- Fibre Glass & Float Glass
- Fast Moving Consumer Goods
- Food, Bakery, Agro Processing

Sectors We Cover *Cont...*

- Fruits & Vegetables Processing
- Ferro Alloys Based Projects
- Fertilizers & Biofertilizers
- Ginger & Ginger Based Projects
- Herbs And Medicinal Cultivation And Jatropha (Biofuel)
- Hotel & Hospitability Projects
- Hospital Based Projects
- Herbal Based Projects
- Inks, Stationery And Export Industries

Sectors We Cover

Cont...

- Infrastructure Projects
- Jute & Jute Based Products
- Leather And Leather Based Projects
- Leisure & Entertainment Based Projects
- Livestock Farming Of Birds & Animals
- Minerals And Minerals
- Maize Processing(Wet Milling) & Maize Based Projects
- Medical Plastics, Disposables Plastic Syringe, Blood Bags
- Organic Farming, Neem Products Etc.

Sectors We Cover *Cont...*

- Paints, Pigments, Varnish & Lacquer
- Paper And Paper Board, Paper Recycling Projects
- Printing Inks
- Packaging Based Projects
- Perfumes, Cosmetics And Flavours
- Power Generation Based Projects & Renewable Energy Based Projects
- Pharmaceuticals And Drugs
- Plantations, Farming And Cultivations
- Plastic Film, Plastic Waste And Plastic Compounds
- Plastic, PVC, PET, HDPE, LDPE Etc.

Sectors We Cover *Cont...*

- Potato And Potato Based Projects
- Printing And Packaging
- Real Estate, Leisure And Hospitality
- Rubber And Rubber Products
- Soaps And Detergents
- Stationary Products
- Spices And Snacks Food
- Steel & Steel Products
- Textile Auxiliary And Chemicals

Sectors We Cover *Cont...*

- Township & Residential Complex
- Textiles And Readymade Garments
- Waste Management & Recycling
- Wood & Wood Products
- Water Industry(Packaged Drinking Water & Mineral Water)
- Wire & Cable

MARKET RESEARCH REPORTS

Objective

- ⌘ To get a detailed scenario of the industry along with its structure and classification
- ⌘ To provide a comprehensive analysis of the industry by covering aspects like:
 - ⌘ Growth drivers of the industry
 - ⌘ Latest market trends
 - ⌘ Insights on regulatory framework
 - ⌘ SWOT Analysis
 - ⌘ Demand-Supply Situation
 - ⌘ Foreign Trade
 - ⌘ Porters 5 Forces Analysis

Objective

- ⌘ To provide forecasts of key parameters which helps to anticipate the industry performance
- ⌘ To help chart growth trajectory of a business by detailing the factors that affect the industry growth
- ⌘ To help an entrepreneur/manager in keeping abreast with the changes in the industry
- ⌘ To evaluate the competitive landscape of the industry by detailing:
 - ⌘ Key players with their market shares
 - ⌘ Financial comparison of present players

Clientele

- ∞Venturist/Capitalists
- ∞Entrepreneur/Companies
- ∞Industry Researchers
- ∞Investment Funds
- ∞Foreign Investors, NRI's
- ∞Project Consultants/Chartered Accountants
- ∞Banks
- ∞Corporates

[Click here for list](#)

Data Sources



Scope & Coverage



Our Team

- ⌘ Our research team comprises of experts from various financial fields:
- ⌘ MBA's
- ⌘ Industry Researchers
- ⌘ Financial Planners
- ⌘ Research veterans with decades of experience

Structure of the Report

- 1. Overview
- 2. Market Analysis
 - 2.1 Growth Drivers
 - 2.2 Emerging Trends in the Industry
 - 2.3 Regulatory Framework
 - 2.4 SWOT Analysis
 - 2.5 Herfindahl–Hirschman Index (HHI)
- 3. Market Forecasts
- 4. Key Players

Structure of the Report

Cont

- ⌘5. Key Financials and Analysis
 - ⌘5.1 Contact Information
 - ⌘5.2 Key Financials
 - ⌘5.3 Financial comparison
- ⌘6. Industry Size & Outlook

Take a look at *NIIR PROJECT CONSULTANCY SERVICES* on
#Street View

<https://goo.gl/VstWkd>

Contact us

NIIR PROJECT CONSULTANCY SERVICES

106-E, Kamla Nagar, Opp. Mall ST,
New Delhi-110007, India.

Email: npcs.ei@gmail.com , info@entrepreneurindia.co

Tel: +91-11-23843955, 23845654, 23845886

Mobile: +91-9097075054, 8800733955

Fax: +91-11-23845886

Website : www.entrepreneurindia.co , www.niir.org

Take a look at ***NIIR PROJECT CONSULTANCY SERVICES*** on #StreetView

<https://goo.gl/VstWkd>

Follow us



➤ <https://www.linkedin.com/company/niir-project-consultancy-services>



➤ <https://www.facebook.com/NIIR.ORG>



➤ <https://www.youtube.com/user/NIIRproject>



➤ https://twitter.com/npcs_in



➤ <https://www.pinterest.com/npcsindia/>

A decorative zigzag line is positioned above the main text.

Thank You

For more information, visit us at:

www.niir.org

www.entrepreneurindia.co